报价延迟最少15分钟:2025/07/21 07:07 EDT
盘前时段
|
||||
|
6 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.96
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.09/0.39
|
|
企业价值
2.37B
|
| 资产负债 |
|
每股账面净值
0.63
|
| 现金流量 |
|
现金流量率
0.00
|
| 损益表 |
|
收益
528.30M
|
|
每股收益
1.21
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 07:07 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants;a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases. |
